tiprankstipranks
Sonnet BioTherapeutics releases ‘What this Means’ segment
The Fly

Sonnet BioTherapeutics releases ‘What this Means’ segment

Sonnet BioTherapeutics (SONN) announced that Pankaj Mohan, PhD, Chief Executive Officer of Sonnet, and John Cini, PhD, Chief Scientific Officer of Sonnet, participated in a Virtual Investor “What this Means” segment released by Sonnet. As part of the segment, Drs. Mohan and Cini discussed the recent U.S. Patent titled, “Interleukin 18 Variants and Fusion Proteins Comprising Same,” covering two of its novel drug candidates, SON-1411 and SON-1400, each containing a modified version of recombinant human interleukin-18.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App